Abstract | PURPOSE: METHODS: Four different uveal melanoma cell lines (OCM-1, OCM-3, OCM-8, 92-1) were treated with PPP alone and in combination with imatinib mesylate, cisplatin, 5-FU and doxorubicin. Cell viability was determined by XTT assay. SCID mice xenografted with uveal melanoma cells were used to determine anti- tumor efficacy of oral PPP in vivo. Tumor samples obtained from the in vivo experiments were analyzed for VEGF and IGF-1R expression by western blotting. RESULTS: PPP was found to be superior to the other anti- tumor agents in killing uveal melanoma cells. Oral PPP inhibited uveal melanoma growth in vivo and was well tolerated by the animals. PPP decreased VEGF expression in the tumors. CONCLUSIONS: Oral PPP is well tolerated in vivo and caused total growth inhibition of uveal melanoma xenografts as well as it decreased the levels of VEGF in the tumors.
|
Authors | Mario A Economou, Sandra Andersson, Diana Vasilcanu, Charlotta All-Ericsson, Eline Menu, Ada Girnita, Leonard Girnita, Magnus Axelson, Stefan Seregard, Olle Larsson |
Journal | Acta ophthalmologica
(Acta Ophthalmol)
Vol. 86 Thesis 4
Pg. 35-41
(Nov 2008)
ISSN: 1755-3768 [Electronic] England |
PMID | 19032680
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Vascular Endothelial Growth Factor A
- picropodophyllin
- Receptor, IGF Type 1
- Podophyllotoxin
|
Topics |
- Administration, Oral
- Animals
- Antineoplastic Agents
(pharmacology)
- Cell Death
- Cell Line, Tumor
- Cell Survival
(drug effects)
- Humans
- Melanoma
(metabolism, pathology, physiopathology)
- Mice
- Mice, SCID
- Neoplasm Transplantation
- Podophyllotoxin
(administration & dosage, analogs & derivatives, pharmacology)
- Receptor, IGF Type 1
(antagonists & inhibitors)
- Transplantation, Heterologous
- Uveal Neoplasms
(metabolism, pathology, physiopathology)
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
|